Tesamorelin / CJC-1295 / Ipamorelin
Triple GH blendTesa CJC IpaEvidence
Preclinical
Typical vial
12 mg
Route
Subcut
Status
United States
What it is
Three growth hormone secretagogues in one vial, commonly 6:3:3. Two of the three do the same job, which is the thing worth knowing before buying it.
What is in the vial
| Compound | Per vial | Share |
|---|---|---|
| TesamorelinGHRH analogue. The only component with an approved indication, and the largest share of the vial. | 6 mg | 50% |
| CJC-1295Also a GHRH analogue, on the same receptor as tesamorelin. That is what makes this the redundant component. | 3 mg | 25% |
| IpamorelinGhrelin receptor agonist. The component that makes this a combination, not a double dose. | 3 mg | 25% |
The ratio is fixed in the vial. Choosing a dose of one component chooses the dose of all the others — you cannot move one without moving them all.
What the contents cost separately
The same masses this vial holds, bought as individual vials, at the cheapest confirmed listing and at the median across vendors. We do not price blend vials themselves — hold this against whatever you are being quoted.
$27–$80
for 12 mg across 3 compounds
| Compound | In this vial | Separately |
|---|---|---|
| Tesamorelin | 6 mg | $14–$42 |
| CJC-1295 | 3 mg | $7–$22 |
| Ipamorelin | 3 mg | $6–$16 |
Buying separately costs more injections and more vials, and buys back the ability to change one dose without changing the others. Prices are read from vendor sites and normalised per milligram; we take no vendor placement. Every listing.
Sold pre-mixed at a 6:3:3 ratio, 6 mg tesamorelin with 3 mg each of CJC-1295 and ipamorelin, and marketed as the most complete growth hormone stack available. It is the natural escalation from the two-compound blends, and it is the one where the reasoning starts to double back on itself.
Tesamorelin and CJC-1295 are both GHRH analogues. They bind the same receptor and do the same thing, so a vial containing both is largely paying twice for one mechanism. The genuine pairing here is a GHRH analogue with ipamorelin, which is a ghrelin-receptor agonist and does something different.
Tesamorelin is the only component with an approved indication, HIV-associated lipodystrophy, and that approval covers tesamorelin alone at a specific dose. Not this mixture.
How it works
Two of the three components act on the same receptor.
Tesamorelin and CJC-1295 are both GHRH analogues, stimulating the pituitary through the growth hormone releasing hormone receptor.
Ipamorelin is a ghrelin receptor agonist, a genuinely separate pathway, and the reason a two-compound GH pairing has a mechanistic argument at all.
Adding a second GHRH analogue to the first does not add a mechanism. It adds mass.
What it is studied for
Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.
Raising growth hormone
Published reviewWhat the blend is sold for.
EvidenceEach component raises GH separately in human studies. The mixture has not been studied, and two components share a receptor.
Regulatory status
Last reviewed 20 Aug 2026. Positions in this category change frequently, so we date the line.
The mixture is not approved anywhere. Tesamorelin alone is FDA-approved for HIV-associated lipodystrophy, at a dose and for a purpose that has nothing to do with this blend.
Identity and clearance
What the molecule is, and how long a dose stays measurable.
Molecule
- Class
- Pre-mixed blend of three secretagogues, 6:3:3 by mass
Dose protocols reported in sources
Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.
| Goal | Dose | Frequency | Route | Units, 12 mg vial | Source | Start this protocol |
|---|---|---|---|---|---|---|
| Commonly described community protocol | 300 mcg – 600 mcg | Nightly, five days on and two off | SubcutaneousTotal blend. At 6:3:3, a 600 mcg draw is 300 mcg tesamorelin with 150 mcg each of CJC-1295 and ipamorelin. | 12.5–25 u | Community practice | Start this |
The doses above in syringe units, for the vial you have:
Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.
CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.
Work out what to draw
Pre-filled with a 12 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.
Draw to 10 units on a 1 mL U-100 syringe. That is 0.1 mL, containing 600 mcg of Tesamorelin / CJC-1295 / Ipamorelin.
10 units sits exactly on a printed line.
BioAlmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.
Open this calculation in the full calculator
Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.
Safety
Reported effects, the situations that need care, and the ones that mean stop.
Reported effects
- Water retention, joint aches, carpal tunnel symptomsPublished review
Common with raised GH
- Raised blood glucose and reduced insulin sensitivityPublished review
Expected from raised GH
- Injection site reactionsCommunity practice
Common, and notably so with tesamorelin
When to stop
- Numbness or tingling in the hands, or wrist pain.
- Persistent swelling of hands, feet or face.
- Raised blood glucose, increased thirst or increased urination.
- Any new lump or unexplained persistent symptom.
Interactions and situations that need care
- Active or previous cancerAvoid
Raising growth hormone raises IGF-1, which is a proliferative signal. This is an absolute contraindication on the approved growth hormone label.
- Diabetes or impaired glucose toleranceAvoid
Growth hormone opposes insulin and raises blood glucose.
- Pregnancy and breastfeedingAvoid
No safety data for the mixture or its components in pregnancy.
- Paying for two GHRH analoguesUse caution
Tesamorelin and CJC-1295 bind the same receptor. Nine of the twelve milligrams in this vial are doing one job, and a two-compound blend of one GHRH analogue with ipamorelin covers the same mechanisms.
- Competing in a tested sportAvoid
Secretagogues are named explicitly in WADA S2.
SportProhibited by the World Anti-Doping Agency under S2: Peptide Hormones, Growth Factors, Related Substances, at all times, in and out of competition. Growth hormone secretagogues are named explicitly in S2.
What to expect
What the sources describe over time, and how confident anyone can be about it.
HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.
- Two of the three components share a receptor. The blend is less complete than it sounds.
- The mixture has never been studied. Component evidence does not transfer to a combination.
- Tesamorelin's approval is for tesamorelin alone, for a specific condition, at a specific dose.
- A GHRH analogue plus ipamorelin covers both mechanisms with two compounds instead of three.
Storage and combinations
How to keep it, and what it does and does not go with.
Storage and handling
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
With other peptides
- MK-677caution
MK-677 is also a ghrelin-receptor agonist, so it overlaps with the ipamorelin share of this blend while adding its own insulin-sensitivity effects.
- CJC-1295 / Ipamorelincaution
This blend contains both of those components plus tesamorelin. Running both means taking CJC-1295 and ipamorelin twice.
- Tesamorelin / Ipamorelincaution
This blend contains both of those components plus CJC-1295. Running both means taking tesamorelin and ipamorelin twice.
Checking your vial
Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it.
Clear, colourless solution
Normal for this blend. There is no coloured component.
Cloudiness or particles
Discard it.
Vocabulary on this page
- Secretagogue
- A substance that makes the body release something it already produces, rather than supplying that thing from outside.
- GHRH analogue
- A synthetic version of the hormone that tells the pituitary to release growth hormone. One of the two receptor routes into a growth hormone pulse.
- Blend
- One vial containing several peptides at a fixed ratio, reconstituted and drawn together.
- Vial
- The small sealed glass container a peptide is sold in, holding a stated mass of freeze-dried powder under a rubber stopper.
- Stack
- Several separate compounds run at the same time, each in its own vial and on its own schedule.
- Injection site
- Where on the body an injection is given. Rotating between sites is standard practice for anything given repeatedly.
Questions
- Is three better than two?
- Not mechanistically. Tesamorelin and CJC-1295 are both GHRH analogues acting on the same receptor, so the third compound adds mass, not a new pathway. The pairing that covers two mechanisms is one GHRH analogue with ipamorelin.
- Does tesamorelin's approval mean anything here?
- Only that one component has been through trials for one condition. It says nothing about this mixture — at this ratio — for these purposes.
References
Everything on this page that came from a source, with the source.
Component evidence for common peptide blends: an assessment of what is known separately
Preclinical peptide literature, 2024 · Assessment of the separate component literatures
Cell culture and rodent models
Every component of the common blends is supported by animal or cell-culture work only. No study has examined any of these combinations as a mixture, so combination evidence is weaker than the single-compound evidence. That is itself preclinical.
Community and vendor practice, unverified
Vendor listings and community protocols, 2026 · Anecdote
Self-selected, unverified
Ratios and doses as vendors sell and users describe them. Ratios vary between sellers, so a blend bought from two vendors is not necessarily the same product.
Tesamorelin / CJC-1295 / Ipamorelin compared with
Also compared with GHK-Cu, Ipamorelin, CJC-1295, Tesamorelin, MK-677, GHRP-2.
Related compounds
MK-677
An orally active ghrelin receptor agonist that raises growth hormone and IGF-1. Not a peptide, and not injected. It is a small molecule taken by mouth.
CJC-1295 / Ipamorelin
The default growth hormone blend: a GHRH analogue with a ghrelin agonist, usually 5 mg of each. Two mechanisms that genuinely differ, unlike the triple.
Tesamorelin / Ipamorelin
An approved GHRH analogue paired with a ghrelin agonist. Sold at three different splits, which matters more here than in most blends.
GHK-Cu
A naturally occurring copper-binding tripeptide with a long history in topical skincare research. Injected use is not what the research studied.
Next
What to do with Tesamorelin / CJC-1295 / Ipamorelin
- Keep a record of itTurn a dose and a schedule into a protocol, then log what you actually take. Tesamorelin / CJC-1295 / Ipamorelin is filled in for you.
- See what it costsPer-milligram prices read from vendor sites and confirmed by a person, so vial sizes compare.
- Check a combinationWhat our profiles record about Tesamorelin / CJC-1295 / Ipamorelin alongside each other compound — including the pairs where nothing is recorded.
Keep this page honest
If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. No clinician reviews these pages.
Page last updated 20 Aug 2026